Clinical trial: Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
Status: RECRUITING
Conditions: Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Clinical Stage III Cutaneous Melanoma AJCC v8|Clinical Stage III Gastric Cancer AJCC v8|Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage III Merkel Cell Carcinoma AJCC v8|Clinical Stage IV Cutaneous Melanoma AJCC v8|Clinical Stage IV Gastric Cancer AJCC v8|Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IV Merkel Cell Carcinoma AJCC v8|Clinical Stage IVA Gastric Cancer AJCC v8|Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IVB Gastric Cancer AJCC v8|Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8|Locally Advanced Cervical Carcinoma|Locally Advanced Endometrial Carcinoma|Locally Advanced Gastric Adenocarcinoma|Locally Advanced Gastroesophageal Junction Adenocarcinoma|Locally Advanced Head and Neck Squamous Cell Carcinoma|Locally Advanced Hepatocellular Carcinoma|Locally Advanced Lung Non-Small Cell Carcinoma|Locally Advanced Malignant Solid Neoplasm|Locally Advanced Melanoma|Locally Advanced Merkel Cell Carcinoma|Locally Advanced Renal Cell Carcinoma|Locally Advanced Skin Squamous Cell Carcinoma|Locally Advanced Triple-Negative Breast Carcinoma|Locally Advanced Unresectable Breast Carcinoma|Locally Advanced Unresectable Cervical Carcinoma|Locally Advanced Unresectable Gastric Adenocarcinoma|Locally Advanced Unresectable Gastroesophageal Junction Adenocarcinoma|Locally Advanced Unresectable Renal Cell Carcinoma|Locally Advanced Urothelial Carcinoma|Metastatic Cervical Carcinoma|Metastatic Endometrial Carcinoma|Metastatic Gastric Adenocarcinoma|Metastatic Gastroesophageal Junction Adenocarcinoma|Metastatic Head and Neck Squamous Cell Carcinoma|Metastatic Hepatocellular Carcinoma|Metastatic Lung Non-Small Cell Carcinoma|Metastatic Malignant Solid Neoplasm|Metastatic Melanoma|Metastatic Merkel Cell Carcinoma|Metastatic Renal Cell Carcinoma|Metastatic Skin Squamous Cell Carcinoma|Metastatic Triple-Negative Breast Carcinoma|Metastatic Urothelial Carcinoma|Pathologic Stage III Cutaneous Melanoma AJCC v8|Pathologic Stage III Gastric Cancer AJCC v8|Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage III Merkel Cell Carcinoma AJCC v8|Pathologic Stage IIIA Cutaneous Melanoma AJCC v8|Pathologic Stage IIIA Gastric Cancer AJCC v8|Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIIB Cutaneous Melanoma AJCC v8|Pathologic Stage IIIB Gastric Cancer AJCC v8|Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIIC Cutaneous Melanoma AJCC v8|Pathologic Stage IIIC Gastric Cancer AJCC v8|Pathologic Stage IIID Cutaneous Melanoma AJCC v8|Pathologic Stage IV Cutaneous Melanoma AJCC v8|Pathologic Stage IV Gastric Cancer AJCC v8|Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IV Merkel Cell Carcinoma AJCC v8|Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage III Gastric Cancer AJCC v8|Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8|Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8|Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage IV Breast Cancer AJCC v8|Skin Squamous Cell Carcinoma|Stage III Cervical Cancer AJCC v8|Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8|Stage III Hepatocellular Carcinoma AJCC v8|Stage III Lung Cancer AJCC v8|Stage III Renal Cell Cancer AJCC v8|Stage III Uterine Corpus Cancer AJCC v8|Stage IIIA Cervical Cancer AJCC v8|Stage IIIA Hepatocellular Carcinoma AJCC v8|Stage IIIA Lung Cancer AJCC v8|Stage IIIA Uterine Corpus Cancer AJCC v8|Stage IIIB Cervical Cancer AJCC v8|Stage IIIB Hepatocellular Carcinoma AJCC v8|Stage IIIB Lung Cancer AJCC v8|Stage IIIB Uterine Corpus Cancer AJCC v8|Stage IIIC Lung Cancer AJCC v8|Stage IIIC Uterine Corpus Cancer AJCC v8|Stage IIIC1 Uterine Corpus Cancer AJCC v8|Stage IIIC2 Uterine Corpus Cancer AJCC v8|Stage IV Cervical Cancer AJCC v8|Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8|Stage IV Hepatocellular Carcinoma AJCC v8|Stage IV Lung Cancer AJCC v8|Stage IV Renal Cell Cancer AJCC v8|Stage IV Uterine Corpus Cancer AJCC v8|Stage IVA Cervical Cancer AJCC v8|Stage IVA Hepatocellular Carcinoma AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVA Uterine Corpus Cancer AJCC v8|Stage IVB Cervical Cancer AJCC v8|Stage IVB Hepatocellular Carcinoma AJCC v8|Stage IVB Lung Cancer AJCC v8|Stage IVB Uterine Corpus Cancer AJCC v8|Triple-Negative Breast Carcinoma|Unresectable Cervical Carcinoma|Unresectable Endometrial Carcinoma|Unresectable Gastric Adenocarcinoma|Unresectable Gastroesophageal Junction Adenocarcinoma|Unresectable Head and Neck Squamous Cell Carcinoma|Unresectable Hepatocellular Carcinoma|Unresectable Lung Non-Small Cell Carcinoma|Unresectable Malignant Solid Neoplasm|Unresectable Melanoma|Unresectable Merkel Cell Carcinoma|Unresectable Renal Cell Carcinoma|Unresectable Skin Squamous Cell Carcinoma|Unresectable Triple-Negative Breast Carcinoma|Unresectable Urothelial Carcinoma
Interventions: DRUG: Cyclophosphamide|BIOLOGICAL: Neoantigen Peptide Vaccine|BIOLOGICAL: Pembrolizumab|BIOLOGICAL: Sargramostim
Study Type: INTERVENTIONAL
Study Design: Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT